RIO DE JANEIRO, Oct 23 (Reuters) - Brazil's health regulator
Anvisa said in a statement on Friday it authorized Sao Paulo's
Butantan Institute biomedical center to import 6 million doses
of a coronavirus vaccine candidate developed by China's Sinovac
The vaccine, known as CoronaVac, is still in phase 3
clinical trials in Brazil and has not been registered for wider
use in Brazil, Anvisa said.
(Reporting by Pedro Fonseca, writing by Jake Spring, editing by